Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Affected assets and topics
REPORT
Why it matters
Novartis is reportedly close to acquiring Avidity Biosciences for over $70 per share, indicating a strategic move to enhance its biotech portfolio. This potential acquisition could strengthen Novartis's position in the biotech sector.
Article tone
Neutral
How the article is written, as reported by the source.
Expected market reaction
Market impact analysis based on bullish sentiment with 85% confidence.
Evidence trail
Evidence
Source
CNBC
Claim
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
AI inference
Bullish · 85%
Generated
2025-10-26 16:26
AI provenance
Technical identifiers
- Provider tag
- openai-gpt-4o-mini
- Analysis version
- openai-gpt-4o-mini
- Article id
- 2599
Original source
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
Original article published by CNBC on October 26, 2025. Analysis and insights provided by AnalystMarkets AI.